Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program

[1]  C. Carella,et al.  Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study , 2022, Cancers.

[2]  C. Tournigand,et al.  Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial. , 2022, The Lancet. Oncology.

[3]  P. Ross-Macdonald,et al.  Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma , 2022, Journal for ImmunoTherapy of Cancer.

[4]  C. Porta,et al.  Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib , 2022, Therapeutic advances in medical oncology.

[5]  M. Brunelli,et al.  Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysis. , 2021, Immunotherapy.

[6]  W. Rathmell,et al.  Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma , 2021, Biomarker Research.

[7]  Daiki Kato,et al.  Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab , 2021, Journal of clinical medicine.

[8]  C. Ciccarese,et al.  Efficacy of VEGFR-TKIs plus immune checkpoint inhibitors in metastatic renal cell carcinoma patients with favorable IMDC prognosis. , 2021, Cancer treatment reviews.

[9]  B. Rini,et al.  A Multi-institutional, Retrospective Analysis of Patients with Metastatic Renal Cell Carcinoma to Bone Treated with Combination Ipilimumab and Nivolumab , 2021, Targeted Oncology.

[10]  K. Bensalah,et al.  Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis. , 2021, Cancer treatment reviews.

[11]  U. Capitanio,et al.  The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care. , 2021, European urology.

[12]  T. Powles,et al.  Outcomes of first-line (1L) ipilimumab and nivolumab (IPI-NIVO) and subsequent therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). , 2021 .

[13]  C. Porta,et al.  Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study) , 2021, Therapeutic advances in medical oncology.

[14]  R. Montironi,et al.  Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: a meta-analysis. , 2021, Immunotherapy.

[15]  Daiki Kato,et al.  Efficacy and Safety of Nivolumab and Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study , 2021, Current oncology.

[16]  M. Remzi,et al.  First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. , 2021, European urology oncology.

[17]  S. Oudard,et al.  Update on the most promising biomarkers of response to immune checkpoint inhibitors in clear cell renal cell carcinoma , 2021, World Journal of Urology.

[18]  S. Buti,et al.  Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis , 2021, Therapeutic advances in urology.

[19]  C. Porta,et al.  721P Ipilimumab and nivolumab compassionate use program in metastatic renal cell carcinoma patients with intermediate or poor IMDC risk score: The large multicenter Italian study , 2020 .

[20]  H. Miyake,et al.  Prognostic Stratification of the IMDC Intermediate Risk Group After Treatment With First-line Molecular-targeted Therapy for Metastatic Renal Cell Carcinoma , 2020, AntiCancer Research.

[21]  G. Brandi,et al.  Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study. , 2020, Clinical genitourinary cancer.

[22]  P. Ross-Macdonald,et al.  Biomarker analyses from the phase III CheckMate 214 trial of nivolumab plus ipilimumab (N+I) or sunitinib (S) in advanced renal cell carcinoma (aRCC). , 2020 .

[23]  M. Milella,et al.  Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review , 2020, Expert review of molecular diagnostics.

[24]  C. Porta,et al.  Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214. , 2019, European urology.

[25]  M. Fiorentino,et al.  Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma. , 2019, Clinical genitourinary cancer.

[26]  C. Porta,et al.  Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis? , 2018, Clinical genitourinary cancer.

[27]  Bohuslav Melichar,et al.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma , 2018, The New England journal of medicine.

[28]  Y. Shao,et al.  On comparing 2 correlated C indices with censored survival data , 2017, Statistics in medicine.

[29]  A. Ravaud,et al.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[30]  T. Choueiri,et al.  External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. , 2013, The Lancet. Oncology.

[31]  M. Regan,et al.  Prognostic factors for overall survival (OS) in patients with metastatic renal cell carcinoma (RCC) treated with vascular endothelial growth factor (VEGF)-targeted agents: Results from a large multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.